| dc.contributor.author | Cetinkaya, Damla | |
| dc.contributor.author | YENİ, Seher Naz | |
| dc.date.accessioned | 2021-03-03T20:06:02Z | |
| dc.date.available | 2021-03-03T20:06:02Z | |
| dc.date.issued | 2020 | |
| dc.identifier.citation | Cetinkaya D., YENİ S. N. , "The Use of Clobazam as Add-on Treatment in Resistant Epilepsy: Our Retrospective Clinical Data", TURKISH JOURNAL OF NEUROLOGY, cilt.26, sa.1, ss.10-13, 2020 | |
| dc.identifier.other | vv_1032021 | |
| dc.identifier.other | av_581e7ce6-24c8-45f7-b69c-05b9f68b1316 | |
| dc.identifier.uri | http://hdl.handle.net/20.500.12627/62079 | |
| dc.identifier.uri | https://doi.org/10.4274/tnd.galenos.2019.22755 | |
| dc.description.abstract | Objective: Patients with drug-resistant focal or generalized epilepsy are important in terms of treatment and polytherapy necessity, adverse effect profiles of drugs, and seizure control difficulties. Clobazam (CLB), which has a lesser sedative effect than other benzodiazepines, is frequently used in different countries. In this study, we aimed to present the results related to the demographic characteristics, adverse effects, and treatment efficacy of patients under CLB treatment. | |
| dc.language.iso | eng | |
| dc.subject | Tıp | |
| dc.subject | Nöroloji | |
| dc.subject | Sağlık Bilimleri | |
| dc.subject | Dahili Tıp Bilimleri | |
| dc.subject | Klinik Tıp (MED) | |
| dc.subject | Klinik Tıp | |
| dc.subject | KLİNİK NEUROLOJİ | |
| dc.title | The Use of Clobazam as Add-on Treatment in Resistant Epilepsy: Our Retrospective Clinical Data | |
| dc.type | Makale | |
| dc.relation.journal | TURKISH JOURNAL OF NEUROLOGY | |
| dc.contributor.department | İstanbul Üniversitesi-Cerrahpaşa , , | |
| dc.identifier.volume | 26 | |
| dc.identifier.issue | 1 | |
| dc.identifier.startpage | 10 | |
| dc.identifier.endpage | 13 | |
| dc.contributor.firstauthorID | 2278588 | |
